|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supporting Table 4. Sensitivity analysis of the summary measure of changes of prescription drug use for financial reasons among cancer survivors versus individuals without a cancer history, results from multivariable logistic regression and stratified by age (18 to 64 versus 65+), 2011-2014 NHIS\*** | | | | | | | | |
|  | **No Cancer Control**  **Group** | **Cancer survivors** | | | | | |
| **Recently Diagnosed (≤ 2 year)** | | | **Previously Diagnosed (> 2 year)** | | |
| **Changes of prescription drug use measures** | **%** | **%** | **OR (95%CI)** | ***P***† | **%** | **OR (95%CI)** | ***P***† |
| **Age 18-64** | **N = 102,608** | **N = 715** | | | **N = 3,519** | | |
| **Summary Measure** **(Items 1-3)** | 9.5 | 14.7 | 2.38 (1.29, 4.38) | .005 | 13.7 | 2.06 (1.57, 2.71) | <.001 |
| **Summary Measure (Items 4-5)** | 19.0 | 29.4 | 2.29 (1.55, 3.38) | <.001 | 25.5 | 1.85 (1.51, 2.26) | <.001 |
| **Summary Measure (Items 1-3 and 5-6)** | 13.0 | 19.7 | 2.27 (1.38, 3.74) | .001 | 17.7 | 1.87 (1.47, 2.40) | <.001 |
| **Age ≥ 65** | **N = 23,657** | **N = 781** | | | **N = 4,546** | | |
| **Summary Measure** **(Items 1-3)** | 4.6 | 4.4 | 1.33 (0.30, 6.00) | .706 | 5.7 | 1.96 (0.86, 4.44) | .107 |
| **Summary Measure (Items 4-5)** | 19.1 | 24.0 | 1.73 (0.73, 4.12) | .211 | 20.3 | 0.96 (0.67, 1.39) | .847 |
| **Summary Measure (Items 1-3 and 5-6)** | 7.0 | 7.1 | 1.05 (0.36, 3.10) | .930 | 7.9 | 1.48 (0.83, 2.66) | .187 |

**\*** All statistical tests were two-sided and all *P* values were derived from multivariable logistic regressions. Shaded areas represent the age group 18 to 64. All logistic regressions controlled for survey year, age, sex, race/ethnicity, education, marital status, health insurance, and geographic region (Northeast, Midwest, South, and West). NHIS: National Health Interview Survey; OR: odds ratio; CI: confidence interval.

† Reflects the statistical significance level of the changes of prescription drug use among cancer survivors versus control group with the same number of comorbid conditions using multivariable logistic regressions.